Business, energy, technology, markets and global industry news from Business News Today

EyePoint Inc.

PharmaDeviceNews EyePoint Inc.
A representative image illustrating EyePoint, Inc.’s DURAVYU wet age-related macular degeneration program after the Phase 3 LUGANO trial missed its primary endpoint despite reducing supplemental treatment burden by 42%.
Pharma & Biotech

DURAVYU Phase 3 setback leaves EyePoint relying on second pivotal wet AMD trial

DURAVYU misses its Phase 3 wet AMD endpoint despite cutting treatment burden 42%. See why EyePoint’s upcoming LUCIA trial is now critical.

Read More
Representative image: Retina specialists review OCT scans as EyePoint’s $EYPT DURAVYU completes enrollment in two Phase 3 diabetic macular edema trials testing six-month dosing against aflibercept.
Pharma & Biotech

DURAVYU pivotal trials move closer to testing a longer-lasting diabetic eye treatment

DURAVYU completes enrollment in two Phase 3 DME trials testing six-month dosing against aflibercept, with results expected in late 2027.

Read More